Welcome to our dedicated page for Aurora Cannabis news (Ticker: ACB), a resource for investors and traders seeking the latest updates and insights on Aurora Cannabis stock.
Aurora Cannabis Inc. reports developments in its global medical cannabis business, including product launches, brand expansion and regulated-market activity across Canada, Europe, Australia and New Zealand. The company serves medical and consumer cannabis markets through brands such as Aurora, MedReleaf, Pedanios, IndiMed, San Raf, Tasty's and Whistler, with GMP-certified manufacturing facilities in Canada and Germany.
Recurring announcements cover new formats such as dried flower, pre-rolls, pastilles and resin cartridges; operating and financial results; international market engagement; capital actions; and governance updates. Aurora's news also reflects its medical-first strategy and use of a global manufacturing network to supply regulated cannabis markets.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Aurora Cannabis Inc. (NASDAQ: ACB, TSX: ACB) has announced the launch of a new tracking program to enhance the wellness journey of cannabis patients. Set to empower users alongside healthcare advice, the Strainprint® App allows users to record symptoms and consumption habits, helping them identify the most suitable cannabis strains and dosages. This initiative aligns with Aurora's commitment to improving patient lives through innovative solutions in the cannabis industry. The Strainprint App is available for free on both the Apple Store and Google Play Store. With a focus on quality and patient well-being, Aurora continues to advance in both medical and recreational cannabis sectors.
Aurora Cannabis (NASDAQ: ACB) announced an exciting new product lineup set to launch in April 2023, featuring original cultivars and strain-specific products aimed at both medical patients and recreational consumers. The new offerings include:
- Pink Diesel '71 and Moon Berry flower strains from Aurora's breeding program.
- Tangerine Dream Cured Resin Gummies infused with strain-specific cured resin.
- Slymer and Trufflez Live Resin Vapes.
The expansion aims to meet the increasing demand for high-quality cannabis products, leveraging Aurora's genetics and research capabilities. Vice President Lana Culley emphasizes a commitment to innovation and quality, aiming to resonate with both consumer expectations and market trends.
Aurora Cannabis has recently repurchased approximately $22.3 million of its convertible senior notes, with a total cash cost of $16.7 million. This strategic move is aimed at reducing debt and annual cash interest expenses, leading to expected savings of $2.6 million annually. Since December 2021, Aurora has repurchased a total of $385 million in notes, realizing annual cash interest savings of around $21 million. The company now holds approximately $79 million in outstanding notes, reinforcing its strong balance sheet, which is among the best in the Canadian cannabis sector. Aurora continues to focus on profitable growth in both the global medical and Canadian adult-use markets.